Bironzo P - Search Results

1

Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in BAP1 or other DNA repair genes.

Betti M, Aspesi A, Ferrante D, Sculco M, Righi L, Mirabelli D, Napoli F, Rondón-Lagos M, Casalone E, Vignolo Lutati F, Ogliara P, Bironzo P, Gironi CL, Savoia P, Maffè A, Ungari S, Grosso F, Libener R, Boldorini R, Valiante M, Pasini B, Matullo G, Scagliotti G, Magnani C, Dianzani I. Betti M, et al. Among authors: bironzo p. Genes Chromosomes Cancer. 2018 Nov;57(11):573-583. doi: 10.1002/gcc.22670. Genes Chromosomes Cancer. 2018. PMID: 30338612

2

Sharing Experience with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors in Lung Cancer: An Italian Expert Panel Discussion.

Gridelli C, Tiseo M, Cortinovis DL, Migliorino MR, Barbieri V, Bironzo P, Bearz A, Attili I, de Marinis F. Gridelli C, et al. Among authors: bironzo p. Curr Oncol. 2023 Nov 20;30(11):10033-10042. doi: 10.3390/curroncol30110729. Curr Oncol. 2023. PMID: 37999149 Free PMC article. Review.

3

Clinical evidence and adverse event management update of patients with RET- rearranged advanced non-small-cell lung cancer (NSCLC) treated with pralsetinib.

Russo GL, Bironzo P, Bennati C, Bonanno L, Catino A, Metro G, Petrini I, Russano M, Passaro A. Russo GL, et al. Among authors: bironzo p. Crit Rev Oncol Hematol. 2024 Feb;194:104243. doi: 10.1016/j.critrevonc.2023.104243. Epub 2023 Dec 20. Crit Rev Oncol Hematol. 2024. PMID: 38135019 Review.

4

HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy.

Yu HA, Goto Y, Hayashi H, Felip E, Chih-Hsin Yang J, Reck M, Yoh K, Lee SH, Paz-Ares L, Besse B, Bironzo P, Kim DW, Johnson ML, Wu YL, John T, Kao S, Kozuki T, Massarelli E, Patel J, Smit E, Reckamp KL, Dong Q, Shrestha P, Fan PD, Patel P, Sporchia A, Sternberg DW, Sellami D, Jänne PA. Yu HA, et al. Among authors: bironzo p. J Clin Oncol. 2023 Dec 10;41(35):5363-5375. doi: 10.1200/JCO.23.01476. Epub 2023 Sep 10. J Clin Oncol. 2023. PMID: 37689979 Free PMC article. Clinical Trial.

5

Immune Checkpoint Inhibitors and Opioids in Patients with Solid Tumours: Is Their Association Safe? A Systematic Literature Review.

Cani M, Bironzo P, Garetto F, Buffoni L, Cotogni P. Cani M, et al. Among authors: bironzo p. Healthcare (Basel). 2022 Dec 30;11(1):116. doi: 10.3390/healthcare11010116. Healthcare (Basel). 2022. PMID: 36611575 Free PMC article. Review.

6

Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancer.

Carnio S, Novello S, Bironzo P, Scagliotti GV. Carnio S, et al. Among authors: bironzo p. Expert Rev Anticancer Ther. 2014 Dec;14(12):1495-513. doi: 10.1586/14737140.2014.949245. Epub 2014 Sep 3. Expert Rev Anticancer Ther. 2014. PMID: 25183305 Free article. Review.

7

Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study.

Lo Iacono M, Monica V, Righi L, Grosso F, Libener R, Vatrano S, Bironzo P, Novello S, Musmeci L, Volante M, Papotti M, Scagliotti GV. Lo Iacono M, et al. Among authors: bironzo p. J Thorac Oncol. 2015 Mar;10(3):492-9. doi: 10.1097/JTO.0000000000000436. J Thorac Oncol. 2015. PMID: 25514803 Free article.

8

Addressing the unmet need in lung cancer: The potential of immuno-oncology.

Scagliotti GV, Bironzo P, Vansteenkiste JF. Scagliotti GV, et al. Among authors: bironzo p. Cancer Treat Rev. 2015 Jun;41(6):465-75. doi: 10.1016/j.ctrv.2015.04.001. Epub 2015 Apr 9. Cancer Treat Rev. 2015. PMID: 25936526 Free article. Review.

9

Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer.

Buttigliero C, Tucci M, Bertaglia V, Vignani F, Bironzo P, Di Maio M, Scagliotti GV. Buttigliero C, et al. Among authors: bironzo p. Cancer Treat Rev. 2015 Dec;41(10):884-92. doi: 10.1016/j.ctrv.2015.08.002. Epub 2015 Aug 31. Cancer Treat Rev. 2015. PMID: 26342718 Free article. Review.

10

Raising the bar for enthusiasm when looking at results of randomized phase II trials-the case of sunitinib in small-cell lung cancer.

Di Maio M, Bironzo P, Scagliotti GV. Di Maio M, et al. Among authors: bironzo p. Transl Lung Cancer Res. 2016 Feb;5(1):89-91. doi: 10.3978/j.issn.2218-6751.2015.07.18. Transl Lung Cancer Res. 2016. PMID: 26958498 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

106 results

Search Page

Filters